share_log

NeuroSense Therapeutics | 424B5: Prospectus

SEC announcement ·  Apr 12 16:35
Summary by Moomoo AI
NeuroSense Therapeutics, a clinical-stage biotechnology company, has announced the offering of 1,732,000 ordinary shares and pre-funded warrants to purchase up to 1,248,000 ordinary shares. The ordinary shares are priced at $1.50 each, while the pre-funded warrants are priced at $1.4999 each, just below the ordinary share price. The pre-funded warrants are immediately exercisable and may be exercised at any time until fully exercised. This offering is being conducted on a 'reasonable best efforts' basis, with A.G.P./Alliance Global Partners serving as the exclusive placement agent. The offering is related to the ordinary shares issuable upon the exercise of the pre-funded warrants sold. Concurrently, NeuroSense is also engaging in a private placement of ordinary warrants to purchase 2,980,000 ordinary...Show More
NeuroSense Therapeutics, a clinical-stage biotechnology company, has announced the offering of 1,732,000 ordinary shares and pre-funded warrants to purchase up to 1,248,000 ordinary shares. The ordinary shares are priced at $1.50 each, while the pre-funded warrants are priced at $1.4999 each, just below the ordinary share price. The pre-funded warrants are immediately exercisable and may be exercised at any time until fully exercised. This offering is being conducted on a 'reasonable best efforts' basis, with A.G.P./Alliance Global Partners serving as the exclusive placement agent. The offering is related to the ordinary shares issuable upon the exercise of the pre-funded warrants sold. Concurrently, NeuroSense is also engaging in a private placement of ordinary warrants to purchase 2,980,000 ordinary shares, exercisable immediately at $1.50 per share and expiring five years from issuance. The securities are being sold under a securities purchase agreement dated April 10, 2024. NeuroSense's ordinary shares and publicly-listed warrants are traded on the Nasdaq Capital Market under the symbols 'NRSN' and 'NRSNW,' respectively. The offering is expected to close on or about April 15, 2024.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more